Investors

Introduction

At Alcobra, we remain deeply committed to developing safe and effective products for the treatment of cognitive disorders including ADHD and Fragile X Syndrome and continuing to deliver value for our stockholders.

Our Investor Relations section is designed to provide you with easy access to company information.

NASDAQ: ADHD

$ 1.06

3:59 PM | Sep 19, 2017
-$0.01
(0.94%)

Day High: 1.08
Day Low:  1.06
Volume:    56,508
Delayed ~20 min., by eSignal.


Events & Presentations

Mar 28, 2017 / 8:00 AM ET